We are proud to announce a new podcast series with Louis-Pierre Gravelle of B&P in collaboration with ISEQ to demystify and explore the intellectual property (IP)...

On October 9, 2012, six retailers, BEST BUY, COSTCO, GAP, OLD NAVY, GUESS? and WAL-MART, filed a motion in the Superior Court of Québec seeking a declaratory judgement against the Office québécoise de la langue française (OQLF) that the use of their trademarks on signage, without a French descriptor, is compliant with the Charter of the French Language (the Charter) and its regulations.

On March 30, 2023, the Supreme Court of Canada dismissed Pharmascience's application for leave to appeal (Docket No. 40400) a decision of the Federal Court of Appeal (FCA) upholding the validity...

On November 30, 2018, Global Affairs Canada issued a news release announcing the signing of the Canada-United States-Mexico Agreement (CUSMA or USMCA) ...

On January 30, 2018, the Government of Canada posted the Comprehensive and Progressive Partnership for Trans-Pacific Partnership (CPTPP) - Backgrounder.

The US Federal Trade Commission is taking aim at native advertising and sponsored content.

Canada's Drug Agency has released new guidance on using artificial intelligence methods to generate real-world evidence for health technology assessments, establishing governance considerations and appraisal principles that emphasize transparency, human oversight, and validation. The agency also launched initiatives supporting precision medicine decision-making, including testing procedure assessments and a pan-Canadian framework for biomarker evaluation in cancer care.

The strategy, titled, "A Prescription for Action: A Pan-Canadian Strategy for Advancing the Appropriate Use of Prescription Medications" provides a 5-year plan to foster a unified national approach that promotes safer, more effective medication use and strengthens health system sustainability.

On November 20, 2024, Health Canada posted Drug shortages in Canada: Fiscal year 2023 to 2024 in review. The review includes an overview of drug shortages...

On February 29, 2024, the Minister of Health announced the introduction of Bill C-64, An Act respecting pharmacare (Pharmacare Act), which "proposes the foundational principles...

Santé Canada et la Food and Drug Administration des États-Unis (la « FDA ») ont créé un programme visant à soutenir la mise en place d'un programme de Demande de partage d'informations (« DPI »)...

As we reported last month, the Minister of Health launched a consultation on a proposed Ministerial Reliance Order that would permit Health Canada to complete the examination of certain parts...

On January 1, 2025, Canada will implement a patent term adjustment (PTA) system to account for unreasonable delays by the Canadian Intellectual Property Office (CIPO) in issuing a patent.

In a recent interview with the World Trademark Review (WTR), Principal Christian Bolduc discusses Bill 96 and its Regulations, and the implications for those doing business in Québec. On June 1, 2022, the Québec...

During a recent meeting, the Canadian Intellectual Property Office (CIPO) revealed plans for a significant reduction in the first examination of Canadian trademark applications not using the pre-approved list of goods...

In Regeneron Pharmaceuticals, Inc v Canada (AG), 2023 FC 768, the Federal Court granted Regeneron's application to add an inventor to its issued patent, which was the subject of pending...

As previously reported, the Federal Court (FC) dismissed Janssen's application for judicial review of the decision of the Office of Submissions and Intellectual Property (OSIP) refusing to list...

On May 28, 2026, the Government of Canada launched a public consultation on the scope of the geographical indications (GIs) regime under the Trademarks Act. The consultation seeks stakeholders' views on how Canada's GI regime could be strengthened and modernized, including whether its scope should be expanded beyond its current categories of protected products.

In a recent interview with CBC News on the cultural appropriation of Inuit designs, Associate Meika Ellis emphasizes the importance of respecting the Inuit community and their cultural heritage.

As previously reported, the Federal Court of Appeal dismissed Apotex's appeal of a decision relating to macitentan (Janssen's OPSUMIT), which found that Apotex would induce infringement of Janssen's patent.